Article Details
Retrieved on: 2022-05-17 12:54:49
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share. The biopharmaceutical company posted ...
Article found on: wraltechwire.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here